Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Head & Neck 1Breast 1

Conditions

Neoplasms, Glandular and Epithelial 2Carcinoma 2Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Gonadal Disorders 1Genital Neoplasms, Female 1Genital Diseases, Female 1Female Urogenital Diseases and Pregnancy Complications 1Female Urogenital Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Adnexal Diseases 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Ocoxin × Gynecologic × Clear all
NCT03549273 2024-02-07

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Catalysis SL

Phase 2 Unknown
62 enrolled
Gynecologic

Carcinoma, Uterine Cervical Dysplasia, Neoplasms, Neoplasms, Glandular and Epithelial

NCT03562897 2022-07-06

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Catalysis SL

Phase 2 Completed
40 enrolled
Gynecologic

Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasm Metastasis, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡